focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Diurnal Group plc

28 Oct 2022 13:26

RNS Number : 5291E
Barclays PLC
28 October 2022
 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR

MORE

Rule 8.3 of the Takeover Code (the "Code")

1.

KEY INFORMATION

(a)

Full name of discloser:

 

Barclays PLC.

(b)

Owner or controller of interest and short

 

 

positions disclosed, if different from 1(a):

(c)

Name of offeror/offeree in relation to whose

DIURNAL GROUP PLC

 

relevant securities this form relates:

(d)

If an exempt fund manager connected with an

 

 

offeror/offeree, state this and specify identity of

 

offeror/offeree:

(e)

Date position held/dealing undertaken:

27 Oct 2022

(f)

In addition to the company in 1(c) above, is the discloser making

NO

 

 

 

disclosures in respect of any other party to the offer?

 

 

2.

POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a)

Interests and short positions in the relevant securities of the offeror or offeree

 

 

to which the disclosure relates following the dealing(if any)

 

Class of relevant security:

5p ordinary

 

Interests

Short Positions

 

Number

(%)

Number

(%)

(1)

Relevant securities owned

 

 

 

 

 

and/or controlled:

 

 

2,315,595

1.36%

0

0.00%

(2)

Cash-settled derivatives:

 

 

 

 

 

and/or controlled:

 

 

0

0.00%

2,315,595

1.36%

(3)

Stock-settled derivatives (including options)

 

 

 

 

 

and agreements to purchase/sell:

 

 

0

0.00%

0

0.00%

 

 

 

 

 

 

 

 

 

TOTAL:

 

 

2,315,595

1.36%

2,315,595

1.36%

(b)

Rights to subscribe for new securities (including directors and other executive

 

 

options)

 

 

 

 

 

 

Class of relevant security in relation to

 

 

 

 

which subscription right exists

 

 

 

 

Details, including nature of the rights

 

 

 

 

concerned and relevant percentages:

 

 

 

 

3.

DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

(a)

Purchases and sales

 

 

 

 

 

Class of relevant

Purchase/sale

Number of

Price per unit

security

 

securities

 

5p ordinary

Purchase

2,315,595

0.2747 GBP

 

 

 

 

 

 

 

 

(b)

Cash-settled derivative transactions

 

Class of

Product

Nature of dealing

Number of

Price per

relevant

description

 

reference

unit

security

 

 

securities

 

5p ordinary

SWAP

Short

2,315,595

0.2747 GBP

 

 

 

 

 

 

 

 

(c)

Stock-settled derivative transactions (including options)

 

(i)

Writing, selling, purchasing or varying

 

Class

Product

Writing,

Number

Exercise

Type

Expiry

Option

of

description

purchasing,

of

price

 

date

money

relevant

 

selling,

securities

per unit

 

 

paid/

security

 

varying etc

to which

 

 

 

received

 

 

 

option

 

 

 

per unit

 

 

 

relates

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(ii)

Exercising

 

 

 

 

 

 

Class of relevant

Product description

Exercising/ exercised against

Number of

Exercise price per

security

 

 

securities

unit

 

 

 

 

 

 

 

 

 

 

 

 

 

(d)

Other dealings (including subscribing for new securities)

 

Class of relevant

Nature of Dealings

Details

Price per unit (if

security

 

 

applicable)

 

 

 

 

4.

OTHER INFORMATION

(a)

Indemnity and other dealings arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding,

 

 

formal or informal, relating to relevant securities which may be an inducement to deal

 

 

or refrain from dealing entered into by the exempt principal trader making the disclosure and any party

 

to the offer or any person acting in concert with a party to the offer:

 

 

 

NONE

(b)

Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between

 

 

the person making the disclosure and any other person relating to:

 

 

(i) the voting rights of any relevant securities under any option; or

 

 

 

(ii) the voting rights of future acquisition or disposal of any relevant securities to which

 

 

any derivative is referenced:

 

 

 

 

 

 

NONE

(c)

Attachments

 

 

 

 

 

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

28 Oct 2022

Contact name:

Large Holdings Regulatory Operations

Telephone number:

020 3134 7213

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETMPBTTMTTTBAT
Date   Source Headline
12th May 20213:44 pmRNSDirector Dealings
12th May 20211:58 pmRNSHolding(s) in Company
12th May 202112:08 pmRNSHolding(s) in Company
12th May 20217:00 amRNSAgreement with Citrine Medicine for Efmody
11th May 20214:43 pmRNSHolding(s) in Company
11th May 20213:25 pmRNSHolding(s) in Company
10th May 202110:26 amRNSResult of General Meeting
23rd Apr 20217:00 amRNSGrant of second European Patent for Alkindi
21st Apr 202111:51 amRNSResult of Placing and Subscription
21st Apr 20217:00 amRNSProposed Placing, Subscription and Open Offer
15th Apr 20219:49 amRNSRequest for Efmody Orphan Designation withdrawn
26th Mar 20212:06 pmRNSSecond Price Monitoring Extn
26th Mar 20212:00 pmRNSPrice Monitoring Extension
26th Mar 202111:57 amRNSEMA issues positive opinion for second product
15th Mar 20217:00 amEQSEdison Investment Research Limited: Diurnal Group (DNL): Initiation - Improving treatments for endocrine disorders
10th Mar 20219:44 amRNSHolding(s) in Company
8th Mar 20215:34 pmRNSHolding(s) in Company
25th Feb 20217:15 amEQSHardman & Co Research: Diurnal Group (DNL): Attention turning to Chronocort(R)
24th Feb 20217:00 amRNSShares and AJ Bell Investor Evening Webinar
23rd Feb 20217:01 amRNSInterim Results
23rd Feb 20217:00 amRNSChronocort agreement with Consilient for Nordics
2nd Feb 20217:01 amRNSChronocort results published in JCEM
27th Jan 20219:00 amRNSPrice Monitoring Extension
27th Jan 20217:00 amRNSChina licencing agreement with Citrine for Alkindi
14th Jan 20217:01 amRNSBusiness and trading update
14th Jan 20217:00 amRNSAgreement with Eton for Alkindi extended to Canada
13th Jan 202110:07 amRNSAgreement with Er-Kim for distribution in Turkey
12th Jan 20217:00 amRNSChronocort MAA Submitted to the UK MHRA
11th Jan 20217:00 amRNSGrant of European Patent for Chronocort
22nd Dec 20203:29 pmRNSIssue of LTIP Awards
11th Dec 20202:02 pmRNSExercise of Options, Issue of Equity and TVR
23rd Nov 20207:00 amRNSExercise of Options, Issue of Equity and TVR
20th Nov 202012:06 pmRNSResult of Annual General Meeting
20th Nov 20207:00 amRNSGrant of European Patent for Alkindi
10th Nov 20207:00 amRNSNotice of Interim Results
2nd Nov 20204:47 pmRNSHolding(s) in Company
30th Oct 202011:34 amRNSHolding(s) in Company
30th Oct 20208:37 amRNSHolding(s) in Company
29th Oct 202010:30 amRNSHolding(s) in Company
29th Oct 20209:25 amRNSDirector Dealings
28th Oct 202012:49 pmRNSResult of General Meeting and Open Offer
21st Oct 20207:00 amRNSMAA for Alkindi submitted to Swissmedic
19th Oct 20207:00 amRNSVesting of LTIP awards
9th Oct 202010:37 amRNSResult of Placing, Open Offer and Notice of GM
9th Oct 20207:00 amRNSProposed Placing and Open Offer
8th Oct 20202:28 pmRNSPosting of Annual Report and AGM Notice
30th Sep 20204:41 pmRNSSecond Price Monitoring Extn
30th Sep 20204:35 pmRNSPrice Monitoring Extension
30th Sep 20208:15 amEQSHardman & Co Research: Diurnal (DNL): And then there were three
30th Sep 20207:00 amRNSAlkindi Sprinkle approved by US FDA

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.